首页> 外文期刊>Asian spine journal. >Perioperative Management of Patients with Hemophilia during Spinal Surgery
【24h】

Perioperative Management of Patients with Hemophilia during Spinal Surgery

机译:脊柱手术中血友病患者的围手术期管理

获取原文
       

摘要

Study Design Single-center retrospective study. Purpose To optimize the perioperative management of patients with hemophilia who are undergoing spinal surgery. Overview of Literature Hemophilia is a rare disease in which there is a tendency of bleeding because of a congenital deficiency in blood coagulation factor activity. There has been no previous report on spinal surgery in patients with hemophilia. Methods The subjects were five patients (all males) with hemophilia who underwent spinal surgery at Nagoya University Hospital. Two patients had hemophilia A (deficiency of factor VIII) and three had hemophilia B (deficiency of factor IX). The mean age at the time of surgery was 63 years (range, 46–73 years). The following surgeries were performed: posterior lumbar interbody fusion (PLIF) in two patients, and lumbar fenestration, cervical laminoplasty and lumbar fenestration, and cervical laminoplasty and PLIF in one patient each. Results Coagulation factor at a mean dose of 4.8 ×10 3 U (range, 3–6 ×10 3 U) was intravenously injected before surgery, and a mean dose of 5.2 ×10 3 U (rang, 4–6 ×10 3 U) was continuously administered for 24 hours after surgery. Factor activity was maintained at ≥80% until postoperative day 14 and at ≥50% thereafter. The average duration of surgery was 178 minutes (range, 133–233 minutes), the estimated blood loss was 661 mL (range, 272–1,344 mL), and a drain tube was left subfascially in place for 2 days in all patients. Reoperation due to postoperative surgical site infection was required in one patient, but there were no complications due to hemorrhagic diathesis. The total dose of coagulation factor administered during hospitalization was 102 ×10 3 U (range, 46–198 ×10 3 U). Conclusions Coordination with a hematologist and dose adjustment of the coagulation factor preparation to maintain a target level of coagulation factor activity facilitated a smooth postoperative course with perioperative control of bleeding during spinal surgery for patients with hemophilia.
机译:研究设计单中心回顾性研究。目的优化正在接受脊柱手术的血友病患者的围手术期管理。文献综述血友病是一种罕见的疾病,由于先天性凝血因子活性不足,有出血的趋势。以前没有关于血友病患者脊柱外科手术的报道。方法研究对象为名古屋大学医院进行脊柱外科手术的5名血友病患者(均为男性)。两名患者患有A型血友病(因子VIII缺乏),三名患者患有B型血友病(因子IX缺乏)。手术时的平均年龄为63岁(46-73岁)。进行了以下手术:两名患者的后腰椎椎间融合术(PLIF),以及一名患者的腰椎开窗术,颈椎椎板成形术和腰椎开窗术,以及颈椎椎板成形术和PLIF术。结果术前静脉注射凝血因子平均剂量为4.8×10 3 U(范围3–6×10 3 U),平均剂量为5.2×10 3 U(范围4–6×10 3 U) )在术后24小时连续服用。直到术后第14天,因子活性一直保持在≥80%,此后≥50%。所有患者的平均手术时间为178分钟(133-233分钟),估计失血量为661 mL(272-1,344 mL),并且将引流管留在了筋膜下2天。一名患者由于术后手术部位感染而需要再次手术,但没有因出血性素质而引起的并发症。住院期间给予凝血因子的总剂量为102×10 3 U(范围46–198×10 3 U)。结论与血液科医师协调并调整凝血因子制剂的剂量以维持凝血因子活性的目标水平,有助于血友病患者在脊柱手术中顺利进行术后围手术期出血控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号